has function has role immunizes against disease immunizes recipient prostate cancer urinary bladder cancer breast cancer melanoma hepatocellular carcinoma Homo sapiens melanoma vaccine therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role prostate cancer vaccine breast cancer vaccine bladder cancer vaccine hepatocellular carcinoma vaccine ESO-1:157-165(165V) peptide vaccine https://github.com/vaccineontology/VO/issues/68 https://pubmed.ncbi.nlm.nih.gov/?term=ESO-1%3A157-165%28165V%29+Peptide Yuanyi (Penny) Pan 1485 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5473 cancer vaccine Justin Song Jie Zheng Oliver He A 9-residued peptide vaccine consisting of amino acids 157 through 165 of the cancer/testis (CT) antigen ESO-1. Modified at position 165 (cysteine to valine) to improve immunogenicity, ESO-1:157-165(165v) peptide administered as a vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. 5473 Gene name: NY-ESO-1 therapeutic cancer vaccine